| HOMA quartiles | Short-term follow-up | ||||
---|---|---|---|---|---|---|
 | I - III | IV | Crude | Adjusted* | ||
 | n = 627 | n = 209 | OR | 95% CI | OR | 95% CI |
Death | 8 (1.3) | 4 (1.9) | 1.5 | 1.0-9.6 | 1.7 | 0.5-5.7 |
MI/PCI | 15 (3.4) | 5 (3.4) | 1.0 | 0.5-2.8 | 1.0 | 0.4-2.8 |
Stroke | 23 (3.7) | 8 (3.8) | 1.0 | 0.5-2.4 | 1.1 | 0.5-2.5 |
Renal failure †| 39 (6.2) | 16 (7.7) | 1.2 | 0.7-2.3 | 1.4 | 0.7-2.7 |
Re-exploration | 54 (8.6) | 22 (10.5) | 1.2 | 0.7-2.1 | 1.3 | 0.8-2.2 |
Infections | 27 (4.3) | 13 (6.2) | 1.5 | 0.7-2.9 | 1.5 | 0.8-3.0 |
CVD composite | 44 (7.0) | 16 (7.7) | 1.1 | 0.6-2.0 | 1.1 | 0.6-2.1 |
 | HOMA quartiles | Long-term follow-up | ||||
 | I - III | IV | Crude | Adjusted ‡ | ||
 | n = 619 | n = 205 | OR | 95% CI | OR | 95% CI |
Death | 20 (3.2) | 10 (4.9) | 1.5 | 0.7-3.3 | 1.7 | 0.7-3.8 |
MI/PCI | 18 (2.9) | 4 (2.0) | 0.7 | 0.2-2.0 | 0.6 | 0.2-1.8 |
Stroke | 12 (1.9) | 1 (0.5) | 0.2 | 0.1-1.9 | 0.3 | 0.1-2.0 |
Infections | 20 (3.2) | 8 (3.9) | 1.2 | 0.5-2.8 | 1.2 | 0.5-2.9 |
CVD composite | 45 (7.3) | 14 (6.8) | 0.9 | 0.5-1.7 | 0.9 | 0.5-1.7 |